ESSA Pharma (EPIX) to Release Earnings on Monday

Key Points

• ESSA Pharma (NASDAQ:EPIX) is set to announce its Q3 2025 earnings on August 4th, with analysts expecting a loss of ($0.24) per share.
• In its previous quarter, ESSA Pharma reported a loss of ($0.14) EPS, beating estimates by $0.05.
• The company's stock is currently trading at $1.88, with a market cap of $83.45 million and a P/E ratio of -2.98.

ESSA Pharma (NASDAQ:EPIX - Get Free Report) TSE: EPI will likely be announcing its Q3 2025 earnings results before the market opens on Monday, August 4th. Analysts expect the company to announce earnings of ($0.24) per share for the quarter.

ESSA Pharma (NASDAQ:EPIX - Get Free Report) TSE: EPI last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.05. On average, analysts expect ESSA Pharma to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

ESSA Pharma Price Performance

NASDAQ EPIX traded up $0.01 on Wednesday, hitting $1.88. 44,802 shares of the company's stock were exchanged, compared to its average volume of 208,430. The firm has a market cap of $83.45 million, a price-to-earnings ratio of -2.98 and a beta of 1.56. The firm's 50-day moving average price is $1.74 and its two-hundred day moving average price is $1.70. ESSA Pharma has a fifty-two week low of $1.40 and a fifty-two week high of $7.88.

ESSA Pharma Company Profile

ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer.